Cardio Diagnostics Holdings, Inc. (CDIO) intrinsic value & 10-year financials
Cardio Diagnostics Holdings, Inc. (CDIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 101.4% a year to $14.8K, with an average return on invested capital of -156.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.69
- Market cap
- $3.0M
- Revenue (FY2025)
- $14.8K
- Revenue growth (6-yr CAGR)
- 101.4%
- ROIC (10-yr avg)
- -156.0%
- Free cash flow (FY2025)
- -$5.9M
CDIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $14.8K | -$6.5M | -$3.71 | -$5.9M | -43737.5% | -75.8% |
| FY2024 | $34.9K | -$8.4M | -$0.31 | -$5.2M | -23977.9% | -123.2% |
| FY2023 | $17.1K | -$8.4M | -$0.66 | -$6.2M | -42440.4% | -231.3% |
| FY2022 | $950 | -$4.7M | -$0.38 | — | -478784.3% | -182.5% |
| FY2021 | $901 | -$620.4K | -$0.13 | — | -68862.2% | -167.0% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cardio Diagnostics Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cardio Diagnostics Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -41.0% ROIC.
Cardio Diagnostics Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cardio Diagnostics Holdings, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-123.23 per share.